4.8 Article

Antibody-conjugated PEGylated cerium oxide nanoparticles for specific targeting of Aβ aggregates modulate neuronal survival pathways

Journal

ACTA BIOMATERIALIA
Volume 8, Issue 6, Pages 2056-2067

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.actbio.2012.01.035

Keywords

Cerium oxide nanoparticle; Targeted therapy; Neurodegeneration; Nanoparticles; Neurotrophins

Funding

  1. RIA
  2. Department of Physics
  3. NSF EECS [0901503]
  4. Div Of Electrical, Commun & Cyber Sys
  5. Directorate For Engineering [0901503] Funding Source: National Science Foundation

Ask authors/readers for more resources

Oxidative stress has been found to be associated with the progression of neurodegenerative diseases such as Alzheimer's, Parkinson's, Lou Gehrig's, etc. In the recent years, cerium oxide nanoparticles (CNPs) have been studied as potent antioxidant agents able to exert neuroprotective effects. This work reports polyethylene glycol (PEG)-coated and antibody-conjugated CNPs for the selective delivering to A beta aggregates, and the protective effect against oxidative stress/A beta-mediated neurodegeneration. In this study PEG-coated and anti-A beta antibody-conjugated antioxidant nanoparticles (A beta-CNPs-PEG) were developed, and their effects on neuronal survival and brain-derived neurotrophic factor (BDNF) signaling pathway were examined. A beta-CNPs-PEG specifically targets the A beta aggregates, and concomitant rescue of neuronal survival better than A beta-CNPs, by modulating the BDNF signaling pathway. This proof of concept work may allow in the future, once validated in vivo, for the selective delivery of CNPs only to affected brain areas. Published by Elsevier Ltd. on behalf of Acta Materialia Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available